Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | PPARD | Q03181 | 1/20 | 0.58 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.58 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.58 |
| ▸ | ZDHHC7 | Q9NXF8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015690 | 0.97 | LCK (0.61) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL4303823 | 0.92 | — | — | |
| SCHEMBL962287 | 0.80 | — | — | |
| SCHEMBL28246883 | 0.80 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL3548195 | 0.80 | LCK (0.54) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL11435214 | 0.78 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL16969703 | 0.78 | LCK (0.57) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL16969549 | 0.78 | LCK (0.57) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL16969706 | 0.78 | LCK (0.57) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL11435217 | 0.78 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611258-B2 | Dual MEK/PI3K inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2968345-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002212-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-01-07 | — | — | US | disclosed |
| WO-2014164942-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2172198-B1 | p27 PROTEIN INDUCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| EP-1982982-B1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | IIKURA HITOSHI | 2011-04-21 | — | — | US | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | LCK 4192/4885PPARD 1372/4885ZDHHC20 4009/4885 |
| US-20160002212-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | MAP2K2, MAP2K1, MAP2K7 | LCK 107/4885PPARD 3718/4885ZDHHC20 2679/4885 |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | LCK 1861/4885PPARD 4048/4885ZDHHC20 2283/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | LCK 1861/4885PPARD 4048/4885ZDHHC20 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.